Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound
Source: SeekingAlpha
2026-02-24 12:50:19 ET
More on Novo Nordisk A/S
- Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture
- Novo Nordisk: Redefine 4 Misses The Mark
- Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly’s Zepbound
Novo Nordisk - Class B
NASDAQ: NONOF
NONOF Trading
-0.98% G/L:
$38.085 Last:
13,168 Volume:
$38.52 Open:
NONOF Latest News
NONOF Stock Data
$217,715,792,624
1,607,906,287
N/A
1546
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
